%0 Generic
%A Jerusalem, G.
%A Prat, A.
%A Salgado, R. F.
%A Reinisch, M.
%A Saura, C.
%A Ruiz Borrego, M.
%A Nikolinakos, P.
%A Filian, J.
%A Ades, F.
%A Huang, N.
%A Mazzei-Abba, A.
%A Tolaney, S. M.
%T Neoadjuvant nivolumab (NIVO) plus palbociclib (PALBO) plus anastrozole (ANA) for estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8
%D 2022
%@ 0923-7534
%U http://hdl.handle.net/10668/21901
%~